secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2022-06-02T23:59:59+00:00
Accession:  0001723128-22-000023
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 1.02, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal refinances $500M credit facility with new $350M revolving facility maturing 2027
--------------------------------------------------------------------------------

- New $350M senior secured revolving credit facility with Truist Bank as administrative agent; matures June 2, 2027.
- Interest rates: ABR + 0.25% to 0.50% or SOFR + 1.25% to 1.50% per annum, depending on excess availability.
- Includes $25M letter of credit subfacility and $35M swingline; incremental increase option up to $150M.
- Prior $500M facility (due May 2023) terminated with no outstanding amounts and no termination penalties incurred.
- Proceeds may be used for capex, acquisitions, working capital, and general purposes under customary negative covenants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000172312822000023/0001723128-22-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000172312822000023/amrx-20220602.htm
  HTML page:      https://secwatch.observer/filing/0001723128-22-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer